Horizons ETFs Made Waves When They Launched the World’s First Psychedelics Stock ETF on the NEO Exchange Early This Year
The Dales Report sat down with Steve Hawkins, the President and CEO of Horizons ETFs for an interview, to learn a little bit more about the behind-the-scenes on creating a Psychedelics ETF like
Horizons Psychedelic Stock Index ETF (NEO: PSYK) from scratch, what investors should know, and where the Psychedelics industry – and others – might be headed. Right now, Hawkings says, the psychedelics industry resembles Cannabis in capital market structure. There’s very few companies in the space, but with big IPOs, and multiple U.S. companies that are looking at moving into Canadian space.
(2)
Highlights include continued progress with phase IIb psilocybin therapy clinical trial, launch of first Centre of Excellence, and expansion of Discovery Center
Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021
First Centre of Excellence, a research facility and innovation lab, established at Sheppard Pratt (Baltimore, Maryland, US)
Discovery Center expanded into network of world-leading scientists developing new optimised psychedelic compounds
Conference call today at 1.00pm GMT (8.00am ET)
LONDON, March 09, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2020 and gave an update on recent progress across its business.